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Abstract
Biallelic expression of insulin-like growth factor-II (IGF2) has been reported to be associated with progression of several
tumors. Here, we report that the promoter usage and expression levels of IGF2 and H19 were altered in cervical carcinoma
showing loss of imprinting. The imprinting status was examined in 32 cervical carcinomas and their matched normal tissues.
Loss of imprinting (LOI) of IGF2 was observed in seven of 18 (39%) informative cases. LOI of H19 gene was detected in five
of 14 informative cases. The usage of promoter P1 was observed in LOI tumors of IGF2, but not in the tumors showing
maintenance of IGF2 imprinting (MOI) and in the normal cervical tissues. Unlike MOI tumors, some LOI tumors revealed
the lack of IGF2 transcription from promoter P3. LOI tumors of IGF2 showed an increased expression level of IGF2 but a
down-regulation of H19 relative to the normal tissues whereas MOI tumors did not reveal significant alterations. These
results suggest that promoter P1 could be involved in the biallelic expression of IGF2 and that the altered expression levels of
IGF2 and H19 gene might be associated with the progression of cervical carcinoma showing biallelic expression of
IGF2. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Carcinoma of the uterine cervix, a common malig-
nancy which a¡ects women worldwide, is the number
one cause of female cancer mortality in developing
countries [1]. Epidemiological studies have suggested
that multiple risk factors could be implicated in the
tumorigenesis of cervical cancer, with human papil-
lomavirus (HPV) being considered the most domi-
nant risk factor [2]. Although HPV infection is com-
mon in young females, only a small portion of
females may develop cervical intraepithelial neoplasia
and even less develop invasive cancer. This phenom-
enon indicates that other than HPV infection, genetic
abnormalities of growth-controlling genes might be
involved in the carcinogenesis of cervical cancer.
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Of growth factors, insulin-like growth factor-II
(IGF2) has been reported to play an important role
in the growth of tumors [3]. The IGF2 gene is ex-
pressed in most normal tissues only from the paternal
allele, with the maternal allele being transcriptionally
silent. This mechanism of gene regulation is known as
genomic imprinting in which some genes are silenced
when transmitted through a particular parental germ
line, resulting in the allele-speci¢c expression of genes
in somatic cells. In case of IGF2, relaxation or loss of
imprinting (LOI) has been implicated in the onset of
several tumors such as epithelial ovarian cancer [4],
breast cancer [5], and uterine leiomyosarcoma [6].
It has been demonstrated that the usage of IGF2
promoters could be changed with the progression of
some tumors. IGF2 is transcribed from four distinct
promoters, P1^P4. The increased usage of promoter
P1 was observed in some Wilms’ tumors [7], and
hepatoblastoma [8]. A previous report showed that
human IGF2 promoters could switch from P2^P4 to
P1 during carcinogenesis [9]. However, it has not
been elucidated whether the promoter usage of
IGF2 could be altered in cervical carcinoma, and if
so whether the alterations of the promoter speci¢city
are limited to the tumors exhibiting LOI.
The H19 gene, which is located closely down-
stream of IGF2, has been reported to be involved
in tumor development and considered to function
as a tumor suppressor [10]. In contrast to IGF2,
H19 is imprinted with the maternal allele being ex-
pressed and the paternal silent. The expression of
H19 has been reported to be a¡ected by the imprint-
ing status of IGF2 in Wilms’ tumor [11].
Although the potential importance of IGF2 LOI
has been reported in several cancers, there is lack of
understanding on the promoter usage and expression
levels of IGF2 and H19 in cervical carcinomas show-
ing monoallelic or biallelic expression of IGF2. We
report here the exclusive usage of IGF2 promoter P1
in the LOI tumor tissues of IGF2, but not in the
tumors showing maintenance of imprinting (MOI)
and in the normal cervical tissues. Moreover,
although the normal tissues and the MOI tumors
of IGF2 did not signi¢cantly di¡er in the expression
levels of IGF2 and H19, the IGF2 LOI tumors
showed signi¢cantly enhanced levels of IGF2 expres-
sion but reduced levels of H19 expression compared
to that of the normal cervical tissues.
2. Materials and methods
2.1. Tissue samples
Tissue samples were obtained from the patients
during the surgical operations at Comprehensive Gy-
necologic Cancer Center, Pundang CHA Hospital
(Kyonggi-do, South Korea) by informed consent.
The tissues were quickly frozen in liquid nitrogen
and stored at 380‡C until analysis. Of the 32 pa-
tients in various stages of tumors of the uterine cer-
vix, 21 patients were diagnosed as cervical carcinoma
(Cx. Ca.), three as Cx. Ca. coexisting with adenocar-
cinoma (Cx. Ca. Adeno), ¢ve as carcinoma-in situ
(CIS), and three as cervical intraepithelial neoplasia
(CIN).
2.2. Preparation of genomic DNA and RNA
Approximately 0.1 g of the frozen tissues were ho-
mogenized using Te£on tissue grinders and genomic
DNA (gDNA) was extracted using a DNAzol (Gibco
BRL, USA) with a concentration of 50 mg tissue per
ml according to the instructions of the manufacturer.
RNA was extracted using an RNeasy Mini kit (Qia-
gen, USA). RNA integrity was determined by elec-
trophoresis on a 1% agarose gel.
2.3. Identi¢cation of genomic polymorphisms
ApaI polymorphism within exon 9 of IGF2 was
screened for heterozygosity of IGF2 gene. For poly-
merase chain reaction (PCR) ampli¢cation of IGF2
gene, the primers were used as follows [6]: sense
strand (P1F), 5P-CTTGGACTTTGAGTCAAAT-
TG-3P, and antisense strand (P1R), 5P-GGTCG-
TGCCAATTACATTTCA-3P. The ampli¢cation re-
sulted in a gene fragment of 292 bp with an ApaI
restriction site at 231 bp. The PCR products were
digested with the restriction enzyme and loaded on
a 4% agarose gel followed by ethidium bromide
staining.
RsaI polymorphism within exon 5 of H19 was
used to analyze the heterozygosity of the H19 gene.
The sense primer (P2F) was 5P-TACAACCACTG-
CACTACCTG-3P (located in exon 4), and the anti-
sense primer (P2R) was 5P-TGGAATGCTT-
GAAGGCGTCT-3P (located in exon 5), resulting
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in a 655 bp gene fragment after PCR ampli¢cation
[6]. The 655 bp PCR products with an RsaI restric-
tion site at 485 bp were digested with 30 U of RsaI,
and electrophoresed on a 4% agarose gel followed by
ethidium bromide staining.
2.4. Allele-speci¢c expression of IGF2 and H19 genes
For heterozygous samples, an allele-speci¢c ex-
pression of IGF2 and H19 genes was further exam-
ined using reverse transcription PCR (RT^PCR) fol-
lowed by enzyme digestion. One Wg of RNA,
extracted from the tissue samples, was reverse tran-
scribed using 1 U reverse transcriptase and random
hexamers (Takara, Japan) in a 20 Wl reaction mixture
at 37‡C for 30 min. The resulting cDNA samples
were heated at 65‡C for 5 min to inactivate the re-
verse transcriptase before PCR. The primers used for
RT^PCR of IGF2 were 5P-TCCTGGAGACCG-
TACTGTGCTA-3P (sense, P3F), and P1R (anti-
sense) as described above. Since primers P3F and
P1R are on exons 8 and 9 of IGF2, respectively,
the PCR using the primer set generated a 1.12 kb
band from cDNA, clearly di¡erentiating from a 1.4
kb gDNA. One Wl of the PCR products was then
used in a second PCR with primers P1F and P1R
under the condition described above. The PCR prod-
ucts were digested with ApaI (yielding either a 292 bp
fragment or a 231 and 61 bp fragment), electropho-
resed through a 4% agarose gel, and visualized with
ethidium bromide. The PCR ampli¢cation of H19
cDNA was performed using the primers P2F and
P2R as described previously [12]. RT^PCR products
were then treated with RsaI yielding both a 575 bp
(undigested) and a 405 bp (digested) fragment in the
heterozygous cases. As a negative control, PCR was
performed with all reaction mixture in the presence
and absence of reverse transcriptase for the possible
contamination of gDNA during cDNA ampli¢ca-
tion.
2.5. Promoter-speci¢c expression of IGF2
Promoter-speci¢c expression of IGF2 was eval-
uated for heterozygous tumor samples and matched
normal tissues using the method previously described
[4]. For promoter P1-speci¢c expression of IGF2, the
primers used in RT^PCR were 5P-GGCCAGAG-
AGCCCAGTCCTGAGGTGA-3P (located on IGF2
exon 2, which is exclusively transcribed from P1 pro-
moter) and 5P-TGGAAGAACTTGCCCACGGGG-
TATCT-3P (located on IGF2 exon 9). For promoter
P3-speci¢c expression of IGF2, the sense primer used
in RT^PCR was 5P-TCCTCCCTGGACAATCAGA-
CGAATTC-3P (located on IGF2 exon 5, which is
exclusively transcribed from P3) and the antisense
primer was as for P1 promoter.
To con¢rm the integrity of the RNA, the glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH)
house keeping gene product was used as an internal
control [4]. The PCR ampli¢cation of a 400 bp frag-
ment of the GAPDH gene was performed using the
reaction mixtures containing deoxynucleotide tri-
phosphate (125 WM each), primers (0.2 mM each),
2 mM MgCl2, 10 mM Tris^HCl, 50 mM KCl, and
1 U of Taq polymerase. The primers used were 5P-
CGTCTTCACCACCATGGAGA-3P (sense, P4F)
and 5P-CGCCCATCACGCCACAGTTT-3P (anti-
sense, P4R). A total of 35 cycles were performed
with 1 min denaturing at 94‡C, 1 min annealing at
64‡C, and 2.5 min extension at 72‡C.
2.6. Semiquantitative analysis of IGF2 and
H19 expression levels
To determine the mRNA expression levels of
IGF2 and H19 genes, semiquantitative RT^PCR
was performed. One Wg of tissue RNA was reverse
transcribed, and ampli¢ed by PCR using primers for
IGF2 (P1F, P1R) and H19 (P2F, P2R) under the
conditions as described above. The same amount of
cDNA was ampli¢ed by PCR for GAPDH using the
primers P4F and P4R. The PCR products were elec-
trophoresed on a 2% agarose gel, and visualized with
ethidium bromide. The density of each band was
measured using a Gel-doc image analyzer (Vilber
Lourmat, France). The band intensities of IGF2
and H19 were normalized with those of correspond-
ing GAPDH.
2.7. Statistics
Statistical analysis of data was performed using
analysis of variance. A p value of less than 0.05
was considered signi¢cant. Duncan’s multiple range
test was used as a post hoc test.
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3. Results
3.1. Genomic polymorphism of IGF2 and H19
DNA specimens from normal and tumor tissues of
32 patients were analyzed for heterozygosity using
polymorphisms at ApaI in the IGF2 gene and at
RsaI in the H19 gene. The representative ¢gures of
IGF2 and H19 polymorphisms after digestion with
each restriction enzyme are shown in Fig. 1A and B,
respectively. Among the 32 normal tissue samples,
we observed 22 heterozygous cases for the IGF2/
ApaI restriction fragment length polymorphism
(RFLP), six homozygous cases for the absence of
this polymorphic site, and four homozygous cases
for the presence of the ApaI site (Table 1). In com-
parison to the matched normal tissues, four cervical
tumor samples lost the heterozygosity. In tumor tis-
sues, 18 heterozygous cases were observed for the
IGF2/ApaI RFLP, indicating an 18.2% loss of heter-
ozygosity. The RFLP of H19/RsaI in the normal
tissues revealed 18 heterozygous cases, six homozy-
gous cases for the absence of RsaI site, and four
homozygous cases for the presence of RsaI. Of the
18 RsaI-heterozygous cases, 14 cases maintained the
heterozygosity in the tumor tissues.
3.2. Biallelic expression of IGF2 and H19 genes
The allele-speci¢c expression of the IGF2 and the
H19 genes was analyzed in all heterozygous cases.
The biallelic expression of IGF2 was detected in sev-
en cases among the 18 informative cases (38.9%)
after digestion with ApaI (Fig. 2A and Table 1).
Among seven LOI tumors of IGF2, one case was
found in CIN stage, two cases were in CIS, and
four cases were in cervical carcinoma. The represen-
tative imprinting results of H19 are shown in Fig.
2B. Five cases of H19 LOI were observed among
14 RsaI-informative cases. Notably, two cases (cases
6 and 12) exhibited LOI in both the H19 and the
IGF2 genes (Table 1).
Fig. 1. Analysis of IGF2 and H19 heterozygosity. From normal
(N) and tumor (T) tissues, gDNA was extracted and ampli¢ed
with IGF2-speci¢c primers. ApaI-digested PCR products of
IGF2 showed two bands of 292 and 231 bp, indicating hetero-
zygosity in both N and T (cases 2, 14). A single band of a 292
or 231 bp band in tumor tissues indicates a loss of heterozygos-
ity (cases 4, 17, 28). (B) RsaI-digested PCR products of H19
yielded two bands of 655 and 485 bp, indicating heterozygosity
of H19 in both N and T (case 5). In some tumors, RsaI-di-
gested PCR products of H19 yielded a 655 bp (case 19) or a
485 bp single band (case 30), indicating a loss of heterozygos-
ity.
Fig. 2. Imprinting result of the IGF2 and H19 genes. Genomic
DNA (gDNA) and cDNA were extracted from tumors. PCR
products of gDNA or cDNA were digested with the ApaI. (A)
In gDNA and cDNA, the undigested allele of IGF2 (292 bp)
and the digested allele of IGF2 (231 bp) band were detected.
The MOI tumors showing monoallelic expression of IGF2 were
observed in the representative cases 2 and 14. The LOI tumor
exhibiting biallelic expression of IGF2 was observed in the rep-
resentative case 20. (B) PCR products of H19 gDNA and
cDNA fragments were digested with RsaI. The digestion of 575
bp cDNA fragments yielded the 405 bp products. The biallelic
expression of H19 was observed in the representative cases 5
and 28.
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3.3. Promoter-speci¢c expression of IGF2 in
normal and tumor tissues
To test whether the promoter usage was altered in
the biallelic expression of IGF2 in cervical carcino-
ma, we studied the promoter-speci¢c expression of
IGF2 in the LOI and MOI tumors of IGF2 and in
their matched normal tissues. The promoter P1-spe-
ci¢c expression was observed in the LOI tumors but
not in the MOI tumors and normal tissues (Fig. 3).
All of the MOI tumors (11 cases) did not show ex-
pression of IGF2 from P1 promoter (Fig. 3A). Sim-
ilarly, all of the normal tissues did not express IGF2
from promoter P1 (Fig. 3A,B). In contrast, among
the seven LOI tumors, six revealed transcription
from P1 promoter (Fig. 3B). One case of the LOI
tumors (case 12) did not show promoter P1-speci¢c
expression.
The promoter P3-speci¢c expression pattern was
also di¡erent between the MOI and the LOI tumors
Table 1
Heterozygosity and imprinting of IGF-2 and H19 in cervical tumors
Case Stage IGF2 H19
Normal gDNA/
ApaI
Tumor gDNA/
ApaI
Tumor cDNA/
ApaI
Normal gDNA/
RsaI
Tumor gDNA/
RsaI
Tumor cDNA/
RsaI
1 Cx. Ca. IIIb b b ab b
2 CIN 3 ab ab a ab ab b
3 Cx. Ca. IIIb ab ab ab ab ab b
4 Cx. Ca. IIIb ab b ab ab a
5 Cx. Ca. Ib a a ab ab ab
6 Cx. Ca. Adeno IIb ab ab ab ab ab ab
7 Cx. Ca. IIIb ab a b b
8 Cx. Ca. Ib ab ab a ab ab b
9 Cx. Ca. IIa ab ab a ab ab a
10 CIS a a b b
11 Cx. Ca. IIa ab ab a b b
12 Cx. Ca. IIb ab ab ab ab ab ab
13 Cx. Ca. IIa a a a a
14 Cx. Ca. IIb ab ab b ab ab ab
15 Cx. Ca. IIa ab ab b b b
16 Cx. Ca. Adeno IIa ab ab b a a
17 CIS ab a b b
18 Cx. Ca. IIb ab ab a ab ab b
19 Cx. Ca. IIb ab ab a ab a
20 Cx. Ca. IIb ab ab ab a a
21 Cx. Ca. IIIb b b ab ab a
22 Cx. Ca. IIb b b a a
23 CIS a a a a
24 CIS ab ab ab ab ab a
25 Cx. Ca. Ib a a a a
26 Cx. Ca. IIa b b a a
27 Cx. Ca. Ia ab ab a a a
28 CIN 3 ab b ab ab ab
29 CIS ab ab ab ab ab a
30 Cx. Ca. IIb ab ab a ab b
31 Cx. Ca Adeno Ib a a b b
32 CIN 2 ab ab ab ab a
a, undigested allele; b, digested allele. Cx. Ca., cervical carcinoma; Cx. Ca. Adeno, cervical carcinoma coexisting with adenocarcino-
ma; CIN, cervical intraepithelial neoplasia; CIS, carcinoma in situ.
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of IGF2. All of the MOI tumors and normal tissues
showed transcription of IGF2 from P3 promoter
(Fig. 4A,B). Unlike this, some LOI tumors showed
either diminished or no expression of IGF2 speci¢c
for promoter P3 (Fig. 4B). The LOI case (case 12)
which showed the lack of expression from P1 pro-
moter (Fig. 3B) revealed the usage of promoter P3
for IGF2 expression (Fig. 4B).
3.4. Expression levels of IGF2 and H19 genes in
normal and tumor tissues
LOI of IGF2 was linked to the altered mRNA
expression levels of IGF2 and H19. The mRNA lev-
els of IGF2, H19, and GAPDH were measured for
the tumor tissues and for the matched normal tissues.
In comparison to the normal tissues, an altered ex-
pression level was observed in the LOI tumors, but
not in the MOI tumors. The expression levels of
IGF2 in the MOI tumors were not signi¢cantly dif-
ferent from those in the normal tissues (Fig. 5A,C).
In contrast, the LOI tumors showed higher mRNA
expression levels of IGF2 than the normal tissues
(Fig. 5B). The semiquantitative analysis indicates
that the ratio of IGF2/GAPDH in the LOI tumors
was 2.26-fold higher than that of the normal tissues
(Fig. 5C). Moreover, the MOI tumors of IGF2 and
the normal tissues did not signi¢cantly di¡er in the
mRNA expression levels of H19 genes (Fig. 6A,C).
However, the mean expression level of H19 was sig-
ni¢cantly lower in the LOI tumors of IGF2 as com-
pared to that of the normal tissues (Fig. 6B,C).
4. Discussion
This study demonstrated that IGF2 promoter P1
might be involved in the biallelic expression of IGF2
in cervical carcinoma. Moreover, we provided evi-
dence that the enhanced expression of IGF2 and
down-regulated expression of H19 could be linked
to the LOI cervical tumors of IGF2, but not to the
MOI tumors.
We observed the LOI of IGF2 gene in 39% of the
Fig. 3. Usage of IGF2 promoter P1 in normal and tumor tis-
sues. The mRNA expression of IGF2 from promoter P1 in the
MOI (A), LOI tumors (B) of IGF2, and their matched normal
tissues was measured by RT^PCR using promoter P1-speci¢c
primers. GAPDH was used as an endogenous reference. Pro-
moter P1-speci¢c products of IGF2 were 600 bp long. The
GAPDH-speci¢c products were 400 bp long.
Fig. 4. Usage of IGF2 promoter P3 in normal and tumor tis-
sues. The usage of IGF2 promoter P3 was measured in the
MOI (A), LOI tumors (B) of IGF2, and their matched normal
tissues by RT^PCR using promoter P3-speci¢c primers. Pro-
moter P3-speci¢c PCR products of IGF2 were 500 bp long.
The GAPDH-speci¢c products were 400 bp long.
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ApaI-informative cases. This frequency is compara-
ble to that observed in ovarian carcinoma [4], but
lower than the value (50%) previously studied for
invasive cervical carcinomas [13]. In our study, LOI
was observed in various stages of cervical tumors
including malignant cancer stage, low grade CIN as
well as noninvasive CIS. The occurrence of LOI in
the various stages of cervical tumors indicates that
LOI of IGF2 may play a role in the development and
maintenance of malignancy in cervical carcinomas.
Meanwhile, the LOI frequency of H19 in this study
is comparable to the ¢ndings reported in lung cancer
[14], but lower than that reported in ovarian tumors
[15].
In this study, the promoter P1-speci¢c expression
Fig. 5. mRNA expression levels of IGF2 genes in normal and
tumor tissues. From MOI (A) and LOI (B) tumors or normal
cervical tissues adjacent to the tumor, mRNA was extracted
and reverse transcribed. The cDNA samples were ampli¢ed us-
ing speci¢c primers of IGF2, and GAPDH, yielding 292 and
400 bp fragments, respectively. (C) The density ratios of IGF2/
GAPDH were determined in normal and tumor samples. The
ratio of IGF2/GAPDH was obtained by dividing the cDNA
band density of IGF2 with that of the corresponding GAPDH.
Fig. 6. mRNA expression levels of H19 genes in normal and
tumor tissues. For the tumor (T) samples of IGF2 and normal
(N) matched tissues, the mRNA expression of H19 was mea-
sured by RT^PCR. From MOI (A) and LOI (B) tumors or
normal cervical tissues adjacent to the tumor, mRNA was ex-
tracted and reverse transcribed. The cDNA samples were ampli-
¢ed using speci¢c primers of H19, and GAPDH, yielding 575
and 400 bp fragments, respectively. (C) The density ratios of
H19/GAPDH were determined in normal and tumor samples.
The ratio of H19/GAPDH was obtained by dividing the cDNA
band density of H19 with that of the corresponding GAPDH.
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was observed in the LOI tumors of IGF2, but not in
the MOI tumors and normal cervical tissues (Fig. 3).
Our observation agrees with the previous report
which showed the activation of the promoter P1 in
LOI ovarian tumors of IGF2 [4]. However, in the
previous study the expression of IGF2 from promoter
P1 in the LOI was not di¡erentiated from that of the
MOI tumors, making it di⁄cult to conclude that the
promoter P1-speci¢c expression was limited to the
LOI tumors. Our results indicate that the transcrip-
tion of IGF2 from promoter P1 in cervical carcino-
mas occurred exclusively in the LOI tumors.
The expression of IGF2 from promoter P1 in al-
most all of the LOI samples in this study indicates
that the activation of the P1 promoter may contrib-
ute to the biallelic IGF2 expression in cervical carci-
nomas. It has been proposed that the IGF2 expres-
sion through the P1 promoter could explain the
biallelic expression patterns in some neoplasms [16].
However, in line with the previous ¢nding on epithe-
lial ovarian cancer [4], we found one case of LOI
cervical tumor which expressed IGF2 from promoter
P3, but not from P1. This suggests that a di¡erent
mechanism might also exist for the biallelic expres-
sion of IGF2 in cervical carcinoma.
Although the normal tissues and the MOI tumors
similarly showed the transcription of IGF2 from pro-
moter P3, the LOI tumors revealed the plasticity dis-
playing either diminished or no expression of IGF2
from promoter P3 as compared to the normal tissues
(Fig. 4). The mechanisms which altered the expres-
sion of IGF2 from promoter P3 in the LOI cervical
tumors need to be further investigated. However, we
cannot exclude the possibility that the hypermethy-
lation of the P3 promoter previously observed in
other tumor cell lines [9] might be associated with
the altered transcription of IGF2 from promoter P3
in cervical carcinomas showing LOI.
LOI of the IGF2 gene, as demonstrated by bial-
lelic expression, appears to be linked to higher ex-
pression levels of IGF2 in cervical carcinoma (Fig.
5). Previously, higher levels of IGF2 mRNA have
been reported in several tumors such as leiomyosar-
comas [6] and meningiomas [17] as compared to that
of normal tissues. IGF2 is known to act as an auto-
crine growth factor and provide the hormonal
changes required for the development of hypertro-
phy. A recent study in knockout mice demonstrated
that the supply of IGF2 could modify the growth of
intestinal adenomas, implicating the functional role
of IGF2 in colorectal tumor progression [18]. Based
on these ¢ndings, the augmented local expression of
IGF2 observed in the LOI tumors may promote the
proliferation and transformation of a benign neo-
plasm to cervical carcinomas.
A loss of IGF2 imprinting has been correlated with
the reduced expression levels of H19 in Wilms’ tumor
[11] and breast tumor [5]. In this study, this correla-
tion was supported by the ¢nding that the LOI cer-
vical tumors of IGF2, but not the MOI tumors,
showed decreased levels of H19 as compared to nor-
mal tissues (Fig. 6). However, our observation does
not agree with the previous study that reported re-
duced expression levels of H19 in ovarian cancer re-
gardless of the imprinting status [4]. The discrepancy
might be partially attributed by the di¡erent pathol-
ogy of ovarian and cervical carcinomas. The mecha-
nism by which LOI of IGF2 is linked to the reduced
expression of H19 in cervical carcinoma still remains
unclear. However, a possibility exists that LOI of the
paternal allele may lead to down-regulation of the
maternal allele and low expression of H19.
In summary, our data indicate that promoter P1
might be involved in the biallelic expression of the
IGF2 gene in the early and late stages of cervical
tumors. Furthermore, the LOI tumors of IGF2, but
not the MOI tumors, were found to be associated
with an increased level of IGF2 expression and a
down-regulation of H19 expression. Taken together,
the alteration in the promoter usage and expression
levels of IGF2 and H19 might potentially contribute
to the carcinogenesis and progression of cervical car-
cinomas with LOI.
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